The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025MBX 1416 Phase 2 trial in ...
GLP-1s can deliver value to patients. But the fact that GLP-1s aren't cost-effective at their current net prices can limit ...